AN2 Therapeutics (ANTX) Change in Acquisitions & Divestments (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $11.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $11.0 million, down 65.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $54.0 million (down 49.33% YoY), and the FY2025 annual result was $74.5 million, down 26.49% from the prior year.
• Change in Acquisitions & Divestments declined to $11.0 million in Q1 2026 per ANTX's latest filing, from $15.5 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $31.5 million in Q1 2025 and troughed at $10.0 million in Q3 2025.
• A 5-year average of $20.5 million and a median of $20.2 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2026: Change in Acquisitions & Divestments surged 66.28% in 2023, then tumbled 65.1% in 2026.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $23.5 million in 2022, then fell by 13.83% to $20.2 million in 2023, then declined by 13.58% to $17.5 million in 2024, then declined by 11.43% to $15.5 million in 2025, then decreased by 29.08% to $11.0 million in 2026.
• Business Quant data shows ANTX's Change in Acquisitions & Divestments at $11.0 million in Q1 2026, $15.5 million in Q4 2025, and $10.0 million in Q3 2025.